Sunil Healthcare Ltd (SUNLOC) — shareholding pattern, promoter holding, financials and share price
About Sunil Healthcare Ltd (SUNLOC)
Sunil Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SUNLOC and on the BSE under scrip code 537253. Its ISIN is INE671C01016.
Incorporated in 1976, Sunil Healthcare Ltd is a certified manufacturer of Empty Hard Gelatin capsules shell and HPMC Capsules shell. [1]
Sunil Healthcare Limited is a leading manufacturer of Empty Hard Gelatin Capsule Shells in India, known for high-quality production standards.
The company has expanded significantly since its inception, increasing its capsule production capacity to 15 billion shells annually by 2021-22.
Listed peers in Pharmaceuticals: Zenith Drugs Ltd, Veerhealth Care Ltd, Bharat Immunological & Biological Corporation Ltd, Source Natural Foods & Herbal Supplements Ltd, Vilin Bio Med Ltd, Onyx Biotec Ltd.
Valuation & Returns
10 Jul 2026At ₹70 a share on 10 Jul 2026, Sunil Healthcare Ltd (SUNLOC) was valued at a price-to-earnings ratio of 17.86x against an industry P/E of 36.41x and a price-to-book of 1.07x on a book value of ₹65.4 per share as of Mar 2025. Solomo computes return on equity of 5.99% and return on capital employed of 6.18% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 17.86x
- Industry P/E
- 36.41x
- P/B
- 1.07x
- EPS (TTM)
- ₹3.92
- Book value / share
- ₹65.4
- ROE
- 5.99%
- ROCE
- 6.18%
- ROA
- 2.48%
- Debt / equity
- 1.02x
- Dividend yield
- 0%
- EBITDA margin
- 16.91%
- 52-week range
- ₹70 – ₹71.01
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sunil Healthcare Ltd (SUNLOC) reported revenue of ₹87.72 crore, net profit of ₹4.01 crore and earnings per share of ₹3.91. That compares with revenue of ₹83.42 crore and net profit of ₹-1.42 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹19.72 crore and net profit ₹1.52 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 119.16 | 110.49 | 90.19 | 83.42 | 87.72 |
| Net profit (₹ cr) | 6.42 | 6.68 | -1.79 | -1.42 | 4.01 |
| EPS (₹) | 6.26 | 6.51 | -1.75 | -1.38 | 3.91 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -0.45% | 3.53% | -10.50% | -7.51% |
| Profit growth | -30.21% | - | -68.84% | 20.67% |
| Stock price CAGR | -4% | 14% | 7% | -16% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.53% of Sunil Healthcare Ltd (SUNLOC) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.1%. Market capitalisation was ₹72 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2013.
Largest disclosed public shareholders in Jun 2026: SHAILESH KUMAR 6.6%, SUNLOC FOODS PRIVATE LIMITED 5.3%, MAGADH TRADERS LTD 1.54%, KANCHAN SUNIL SINGHANIA 1.21%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.53% | - | - | 0.1% | 26.47% |
| Mar 2026 | 73.53% | - | - | 0.1% | 26.47% |
| Dec 2025 | 73.53% | - | - | 0.1% | 26.47% |
| Sep 2025 | 73.53% | - | - | 0.1% | 26.47% |
| Jun 2025 | 73.53% | - | - | 0.1% | 26.47% |
| Mar 2025 | 73.53% | - | - | 0.1% | 26.47% |
| Dec 2024 | 73.53% | - | - | 0.1% | 26.47% |
| Sep 2024 | 73.53% | - | - | 0.1% | 26.47% |